Cargando…
Does the Number of Bifunctional Chelators Conjugated to a mAb Affect the Biological Activity of Its Radio-Labeled Counterpart? Discussion Using the Example of mAb against CD-20 Labeled with (90)Y or (177)Lu
[Image: see text] There has been considerable interest in developing a monoclonal antibody (mAb) against-CD-20 (for example, Rituximab) modified by bifunctional chelating agents (BCA) for non-Hodgkin’s lymphoma radioimmunotherapy. Therefore, many researchers have modified this monoclonal antibody by...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical Society
2022
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9109692/ https://www.ncbi.nlm.nih.gov/pubmed/35442675 http://dx.doi.org/10.1021/acs.jmedchem.1c02044 |
_version_ | 1784708944094035968 |
---|---|
author | Karczmarczyk, Urszula Sawicka, Agnieszka Garnuszek, Piotr Maurin, Michał Wojdowska, Wioletta |
author_facet | Karczmarczyk, Urszula Sawicka, Agnieszka Garnuszek, Piotr Maurin, Michał Wojdowska, Wioletta |
author_sort | Karczmarczyk, Urszula |
collection | PubMed |
description | [Image: see text] There has been considerable interest in developing a monoclonal antibody (mAb) against-CD-20 (for example, Rituximab) modified by bifunctional chelating agents (BCA) for non-Hodgkin’s lymphoma radioimmunotherapy. Therefore, many researchers have modified this monoclonal antibody by attaching different BCA moieties and evaluated their biological activities in terms of in vitro study and in vivo study in healthy and tumor xenografted rodents. This mini-perspective reviews the in vitro studies, the immunoreactivity and physiological distribution studies: organ-to-blood and the tumor-to-organ ratio of conjugates with different numbers of chelators per mAb. We set up a null hypothesis that states there is no statistical significance between the biological activity of monoclonal antibody (Rituximab) and the number of conjugated bifunctional chelators. Overall, we have concluded that there is no strong evidence for this hypothesis. However, the literature data should be questioned due to the potential lack of uniform study methodology. |
format | Online Article Text |
id | pubmed-9109692 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | American Chemical Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-91096922023-04-20 Does the Number of Bifunctional Chelators Conjugated to a mAb Affect the Biological Activity of Its Radio-Labeled Counterpart? Discussion Using the Example of mAb against CD-20 Labeled with (90)Y or (177)Lu Karczmarczyk, Urszula Sawicka, Agnieszka Garnuszek, Piotr Maurin, Michał Wojdowska, Wioletta J Med Chem [Image: see text] There has been considerable interest in developing a monoclonal antibody (mAb) against-CD-20 (for example, Rituximab) modified by bifunctional chelating agents (BCA) for non-Hodgkin’s lymphoma radioimmunotherapy. Therefore, many researchers have modified this monoclonal antibody by attaching different BCA moieties and evaluated their biological activities in terms of in vitro study and in vivo study in healthy and tumor xenografted rodents. This mini-perspective reviews the in vitro studies, the immunoreactivity and physiological distribution studies: organ-to-blood and the tumor-to-organ ratio of conjugates with different numbers of chelators per mAb. We set up a null hypothesis that states there is no statistical significance between the biological activity of monoclonal antibody (Rituximab) and the number of conjugated bifunctional chelators. Overall, we have concluded that there is no strong evidence for this hypothesis. However, the literature data should be questioned due to the potential lack of uniform study methodology. American Chemical Society 2022-04-20 2022-05-12 /pmc/articles/PMC9109692/ /pubmed/35442675 http://dx.doi.org/10.1021/acs.jmedchem.1c02044 Text en © 2022 The Authors. Published by American Chemical Society https://creativecommons.org/licenses/by-nc-nd/4.0/Permits non-commercial access and re-use, provided that author attribution and integrity are maintained; but does not permit creation of adaptations or other derivative works (https://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Karczmarczyk, Urszula Sawicka, Agnieszka Garnuszek, Piotr Maurin, Michał Wojdowska, Wioletta Does the Number of Bifunctional Chelators Conjugated to a mAb Affect the Biological Activity of Its Radio-Labeled Counterpart? Discussion Using the Example of mAb against CD-20 Labeled with (90)Y or (177)Lu |
title | Does the Number
of Bifunctional Chelators Conjugated
to a mAb Affect the Biological Activity of Its Radio-Labeled Counterpart?
Discussion Using the Example of mAb against CD-20 Labeled with (90)Y or (177)Lu |
title_full | Does the Number
of Bifunctional Chelators Conjugated
to a mAb Affect the Biological Activity of Its Radio-Labeled Counterpart?
Discussion Using the Example of mAb against CD-20 Labeled with (90)Y or (177)Lu |
title_fullStr | Does the Number
of Bifunctional Chelators Conjugated
to a mAb Affect the Biological Activity of Its Radio-Labeled Counterpart?
Discussion Using the Example of mAb against CD-20 Labeled with (90)Y or (177)Lu |
title_full_unstemmed | Does the Number
of Bifunctional Chelators Conjugated
to a mAb Affect the Biological Activity of Its Radio-Labeled Counterpart?
Discussion Using the Example of mAb against CD-20 Labeled with (90)Y or (177)Lu |
title_short | Does the Number
of Bifunctional Chelators Conjugated
to a mAb Affect the Biological Activity of Its Radio-Labeled Counterpart?
Discussion Using the Example of mAb against CD-20 Labeled with (90)Y or (177)Lu |
title_sort | does the number
of bifunctional chelators conjugated
to a mab affect the biological activity of its radio-labeled counterpart?
discussion using the example of mab against cd-20 labeled with (90)y or (177)lu |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9109692/ https://www.ncbi.nlm.nih.gov/pubmed/35442675 http://dx.doi.org/10.1021/acs.jmedchem.1c02044 |
work_keys_str_mv | AT karczmarczykurszula doesthenumberofbifunctionalchelatorsconjugatedtoamabaffectthebiologicalactivityofitsradiolabeledcounterpartdiscussionusingtheexampleofmabagainstcd20labeledwith90yor177lu AT sawickaagnieszka doesthenumberofbifunctionalchelatorsconjugatedtoamabaffectthebiologicalactivityofitsradiolabeledcounterpartdiscussionusingtheexampleofmabagainstcd20labeledwith90yor177lu AT garnuszekpiotr doesthenumberofbifunctionalchelatorsconjugatedtoamabaffectthebiologicalactivityofitsradiolabeledcounterpartdiscussionusingtheexampleofmabagainstcd20labeledwith90yor177lu AT maurinmichał doesthenumberofbifunctionalchelatorsconjugatedtoamabaffectthebiologicalactivityofitsradiolabeledcounterpartdiscussionusingtheexampleofmabagainstcd20labeledwith90yor177lu AT wojdowskawioletta doesthenumberofbifunctionalchelatorsconjugatedtoamabaffectthebiologicalactivityofitsradiolabeledcounterpartdiscussionusingtheexampleofmabagainstcd20labeledwith90yor177lu |